BTK and B-cell chronic lymphocytic leukemia: A number of targeted therapies appear to have promise in treating CLL (such as Bruton's tyrosine kinase (BTK) and the delta isoform of phosphoinositol 3-kinase (PI3Kδ) inhibitors [1, 2] and BCL2 family inhibitors [3, 4]).